HELP:NASDAQ
Cybin Inc
10,72 US$
arrow_upward
+2,00%(+0,21) 1 d
10,70 US$
arrow_downward
−0,19% (−0,020)bedtimeEfter stängning
Stängd: 8 okt., 16:00:01 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för HELP …
Öppen
10,50 US$
Högt
10,79 US$
Lågt
10,19 US$
Genomsn. vol.
1,60 mn
Volym
1,12 mn
52v högst
15,15 US$
52v lägst
3,76 US$
Beta
0,53
Utestående aktier
73,06 mn
Antal anställda
100
Öppen
10,50 US$
Högt
10,79 US$
Lågt
10,19 US$
Genomsn. vol.
1,60 mn
Volym
1,12 mn
52v högst
15,15 US$
52v lägst
3,76 US$
Beta
0,53
Utestående aktier
73,06 mn
Antal anställda
100
Nyheter och artiklar
Från webbkällor och nyhetspartner
TipRanks
·
för 8 timmar sedan
Helus Pharma Sets Investor Presentation to Spotlight Late-Stage Mental Health Pipeline
Investing.com
·
för 8 timmar sedan
H.C. Wainwright reiterates Helus Pharma stock rating at buy
kalkine.ca
·
för 1 dag sedan
Helus Pharma Stock Under Pressure: Clinical Risk and Bearish Momentum Raise Correction Concerns
Profil
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Om Cybin Inc